Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.26M | -90.90M | -84.71M | -65.05M | -65.69M |
| Total Depreciation and Amortization | 611.00K | 641.00K | 632.00K | 659.00K | 666.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.20M | 13.54M | 17.22M | 14.93M | 7.54M |
| Change in Net Operating Assets | 8.97M | 4.96M | 2.62M | -12.19M | 3.09M |
| Cash from Operations | -81.48M | -71.75M | -64.23M | -61.65M | -54.39M |
| Capital Expenditure | -318.00K | -281.00K | -157.00K | -43.00K | -783.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 63.02M | 38.81M | 82.42M | 34.55M | 99.29M |
| Cash from Investing | 62.70M | 38.53M | 82.26M | 34.51M | 98.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 113.54M | 2.36M | 65.00K | 1.15M | 12.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 113.54M | 2.36M | 65.00K | 1.15M | 12.13M |
| Foreign Exchange rate Adjustments | -104.00K | -6.00K | 632.00K | -64.00K | -1.16M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.65M | -30.87M | 18.72M | -26.06M | 55.09M |